INVESTIGADORES
HEBERT Elvira Maria
congresos y reuniones científicas
Título:
ISAPP- SFA annual Meeting
Autor/es:
CATALDO, P.G.; BULACIOS, G.A.; NAJA, J.; ELEAN, M.D.; POSSE DE CHAVES, E.; TARANTO, M.P.; BEAUQUIS, J.; HEBERT, E. M.; SAAVEDRA, L.
Reunión:
Congreso; ISAPP- SFA annual Meeting; 2023
Institución organizadora:
ISAPP- SFA annual Meeting. 25 al 28 de junio de 2023. Denver, Colorado, E.E.U.U
Resumen:
Abstract:One consequence of the increase in longevity is the appearance of diseases associated with aging such asdementia. Alzheimer´s disease (AD) is the most common type of dementia. Currently, there is no definitivetreatment for AD, cholinesterase inhibitors and memantine are the current mainstays of the treatment.Numerous nutritional interventions for AD are currently under study. To date, there is scientific evidence onthe use of psychobiotics, those probiotics that provide a potential benefit to mental health. This workrepresents the first report on the daily oral administration (30 days) of Lactobacillus delbrueckii subsp. lactisCRL 581 (1x10E8), an in vitro AChE inhibitor and Levilactobacillus brevis CRL 2013 (1x 10E9), a GABA producerstrain, on oxidative stress and cholinergic dysfunction in a scopolamine-mice model. Scopolamine, acholinergic receptor blocker, produced memory loss, cognitive impairment and increased AChE activity,mimicking those alterations observed in AD. Administration of CRL581 showed a decrease in AChE activityin brain homogenates of scopolamine-treated mice; CRL2013 increased catalase activity and the amount ofreduced glutathione. In addition, both strains were able to reduce malondialdehyde, an end-product oflipid peroxidation, considered to be one of the markers of reactive oxygen species generation. Shot-gunproteomic analysis of scopolamine- and psychobiotics-brain homogenates revealed unique differentialexpression patterns. Our results show that both strains evaluated here ameliorate oxidative stress markersin a scopolamine-mice model supporting the development of a functional supplement containinggenetically and functionally characterized psychobiotics for non-pharmacological intervention of thoseaffected with AD.</div></div></body></html>